Opus Genetics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRD research report →
Companyopusgtx.com
Opus Genetics, Inc. , a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.
- CEO
- George Magrath
- IPO
- 2015
- Employees
- 18
- HQ
- Durham, MI, US
Price Chart
Valuation
- Market Cap
- $361.40M
- P/E
- -36.08
- P/S
- 30.16
- P/B
- -84.17
- EV/EBITDA
- -5.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 49.64%
- Op Margin
- -359.13%
- Net Margin
- -892.36%
- ROE
- 6068.79%
- ROIC
- -74.91%
Growth & Income
- Revenue
- $14.20M · 29.15%
- Net Income
- $-49,591,000 · 13.80%
- EPS
- $-0.80 · 62.79%
- Op Income
- $-38,599,000
- FCF YoY
- -37.84%
Performance & Tape
- 52W High
- $5.81
- 52W Low
- $0.90
- 50D MA
- $4.99
- 200D MA
- $2.85
- Beta
- 0.63
- Avg Volume
- 918.11K
Get TickerSpark's AI analysis on IRD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 23, 26 | YERXA BENJAMIN R | sell | 7,470 |
| Apr 23, 26 | SCHACHLE JOSEPH K | sell | 4,697 |
| Apr 23, 26 | Zaremba Rabourn Amy | sell | 1,641 |
| Apr 23, 26 | Magrath George | sell | 9,511 |
| Apr 23, 26 | Jayagopal Ashwath | sell | 7,542 |
| Apr 23, 26 | Gagnon Robert E. | sell | 7,842 |
| Apr 20, 26 | Rodgers Richard J | other | 24,367 |
| Apr 20, 26 | MANUSO JAMES S J | other | 24,367 |
| Apr 20, 26 | Graves Adrienne L | other | 24,367 |
| Apr 20, 26 | Gallagher Cam | other | 24,367 |
Our IRD Coverage
We haven't published any research on IRD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IRD Report →